Abstract The objective of this study was to elucidate the role of magnesium sulfate in patients with subarachnoid hemorrhagic (SAH) brain injury. Studies for the metaanalysis were identified from PubMed
Introduction
Subarachnoid hemorrhage (SAH) is a devastating event accounting for 5% of all stroke types with an estimated incidence of nine per hundred thousand persons each year [1] . On average, 12% of patients die before reaching medical attention, with 40% of those who survive dying within the first month [2] .
Yet, despite the advances that have been made both surgically and medically for patients who experience an SAH, morbidity and mortality rates have failed to move appropriately [3] . This is partly attributed to the lack of effective therapeutic approach in dealing with cerebral ischemia as a result of cerebral vasospasm, one of the major consequences seen in SAH [4] . Considered one of the most important causes of poor outcome in SAH, cerebral vasospasm most frequently develops between 4 and 10 days after an injury [6] [7] [8] . Current prophylactic therapies include oral calcium channel blockers, rho-kinase inhibitors, and cisternal irrigation with milrinone [5] .
Despite aggressive prophylactic therapy, cerebral vasospasm continues to be as high as 67%. Once the onset occurs, very few therapies including hypertensive-hypervolemic hemodilution therapy, intra-arterial injection of papaverin, and transluminal balloon angioplasty are available. Therefore, a new therapeutic approach is warranted to combat the effects of cerebral vasospasm.
Magnesium sulfate has been suggested in several clinical studies to reduce the risks of delayed cerebral ischemia and with very limited adverse effects [11] [12] [13] [14] . Theorized to block the release of excitatory amino acids as well as act as a vasodilator on cerebral arteries [20] [21] [22] , magnesium sulfate has been used for years as an effective treatment for vasospasm in obstetric diseases, including preeclampsia and full-blown eclampsia [9, 10] .
In this study, we performed a systematic review and meta-analysis of patients who experienced an SAH and assess the efficacy and safety of magnesium sulfate treatment. We hope to determine whether magnesium sulfate treatment will reduce the risk of delayed cerebral ischemia caused by cerebral vasospasm and improve morbidity and mortality among these patients.
Methods

Search Methods
Literature search engines that were employed for this study include Randomized clinical trials looking directly at magnesium sulfate treatment and placebo in patients with SAH were included. Uncontrolled trials as well as quasi-randomized controlled trials were not employed. Participation was restricted to those individuals, male or female, older than 18 years of age who presented within a 4-day time window after SAH. Patients who were pregnant, in renal failure, hypotensive, bradycardic, had signs of hypermagnesaemia, neuromuscular disease, or faced imminent death were excluded from the study. The diagnosis of SAH had to be confirmed on proper imaging including computerized tomography and/or magnetic resonance angiography and cerebral angiography. All patients had to have received standard medical care and proper SAH management. Treatment with magnesium sulfate by intravenous infusion must have started within 4 days of hemorrhage onset and maintained for a minimum of 12 days.
Outcomes were assessed within 6 months of the event looking at clinical signs of ischemia and/or death. In addition, adverse effects including any case fatalities were measured.
Data Collection and Bias Assessment
Independent review was conducted by two authors who assessed the standardization of this study. These authors evaluated the level and method of randomization, presence of blinding, whether follow-ups/dropouts were reported, and, if so, ensuring the rate was <20% [23] . The authors rated the quality of allocation concealment as adequate if there was a double-blind treatment, unclear if the treatment concealment was unknown, and inadequate if there was single or no blinding of treatment [24] . Further assessment of bias score risk was obtained using the modified Jadad scale [25] .
Data Analysis
All data analysis was conducted using the Review Manager 5.01 software (Cochrane Collaboration, Oxford, UK, www. cc-ims.net). A heterogeneity test was conducted using either a model with fixed effects if the test was not statistically significant (p>0.05) or with random effects if the test was statistically significant (p≤0.05). Treatment outcomes were estimated using relative risk (RR) with a 95% confidence interval (CI).
Results
Five studies published between 2002 and 2008 comparing magnesium sulfate treatment with placebo in patients with SAH were obtained and included in the analysis. These studies reported on a total of 482 patients of whom 243 (50.4%) received treatment and 239 (49.6%) received placebo. The study descriptions can be found in Tables 1  and 2 . All five studies scored 4 or more stars on the modified Jadad scale with the method quality descriptions found in Table 2 . 
Study or Subgroup
Total (95% CI)
Total events Heterogeneity: Chi² = 1.11, df = 4 (P = 0.89); I² = 0% Test for overall effect: Z = 0.64 (P = 0.52) 
Meta-analysis
There was a statistically significant difference reported in the 6-month outcome between the placebo and treatment groups (RR 0.73, p = 0.01; CI 0.57-0.93; Fig. 1 ) as well as among the data collected from the delayed cerebral ischemia assessment (RR 0.66, p = 0.01; CI 0.47-0.92; Fig. 2 ). Case fatality assessment at 3 to 6 months did not show statistically significant data (RR 0.88, p = 0.52; CI 0.61-1.29; Fig. 3 ).
Adverse Effects
Four of five studies reported adverse effects with the treatment group including one patient experiencing hypotension, two with bradycardia, one with atrial fibrillation, three with hypermagnesemia, and one with renal failure. In another study, two patients reported a warm feeling during the start of magnesium sulfate infusion, while another patient complained about acute injection site pain (Table 1) .
Discussion
The aim of this study was to investigate the role of magnesium sulfate in subarachnoid hemorrhagic brain injury by collecting and analyzing data from previously published works. In this meta-analysis, five papers were reviewed looking at the effects of magnesium sulfate versus placebo treatments. Two points were established after completion of the analysis. First, treatment with magnesium sulfate reduces poor outcome, including mortality and morbidity, associated with SAH. Second, prophylactic treatment with magnesium sulfate significantly decreases the risk of delayed cerebral ischemia after SAH. To the best of our knowledge, this is the first metaanalysis looking at the effects of magnesium sulfate on SAH outcome.
The improvements with magnesium sulfate treatment are consistent in all five studies. However, the mechanism behind its effects still remains unclear. Hypotheses allude to the possibility of an N-methly-D-aspartate receptor causing relaxation of the cerebral arteries [16, 17] . This can be explained by the magnesium ion having a key binding position on the receptor. Other studies have proposed that magnesium may act as a nonspecific antagonism of all subtypes of voltage-sensitive calcium channels [18, 19] . This could explain a previously published study comparing magnesium sulfate to nimodipine therapy in SAH which found that magnesium sulfate had similar, if not better, efficacy compared to nimodipine [26] . Determining the mechanism behind treatment with magnesium sulfate is beyond the scope of this study; however, it is recognized that the need to understand how it exerts its effects is important to understanding both improved and adverse outcomes.
Magnesium sulfate has been shown to be beneficial in treatment management of patients with SAH. Based on the results collected in this review, the authors of this paper suggest prophylactic magnesium sulfate treatment as an effective option in the management of SAH. Understandably, the need for larger scale studies is warranted. Fig. 3 Meta-analysis of delayed cerebral ischemia (DCI)
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